top of page
November 6, 2021
Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis - Society for Immunotherapy of Cancer
Carpenter et al.
November 6, 2021
Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis - Society for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer | Carpenter, et al.
October 10, 2021
Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial
Carpenter et al.
June 9, 2021
American Society of Clinical Oncology - The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma
Journal of Clinical Oncology | Adams et al.
May 4, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
Cancer Medicine | Chick et al.
PUBLICATIONS & PRESENTATIONS
CONTACT US
We would love to hear from you. Tell us a little about yourself and we will reach out.
Elios Therapeutics, LLC 5900 Southwest Parkway, Building 2, Suite 220
Austin, TX 78735
bottom of page